Homemarket Newsstocks News

Biocon inks agreement with Zentiva for commercialisation of diabetes drug in Europe 

Biocon inks agreement with Zentiva for commercialisation of diabetes drug in Europe 

Biocon inks agreement with Zentiva for commercialisation of diabetes drug in Europe 
Read Time
1 Min(s) Read
Profile image

By CNBCTV18.com Nov 24, 2022 7:44 PM IST (Published)

Biocon will also retain the right to commercialise this product under its own brand in the region.

wealth-desk wealth-desk

Buy / Sell Biocon share

Recommended Articles

View All

Biocon Ltd. has entered into a partnership agreement with Zentiva for the commercialisation of the Liraglutide drug in the European market. Liraglutide injection is used in the treatment of Type 2 diabetes and obesity.


As per the agreement, Biocon will be responsible for manufacturing and supplying Liraglutide to Zentiva and for the commercialisation of the drug across 30 countries in Europe.

Biocon will also retain the right to commercialise this product under its own brand in the region.

Zentiva, a European pharmaceutical major, has a strong legacy in branded generics across several therapeutic areas, including diabetes, cardiology, respiratory, and oncology.

With a focus on research and development, and four flagship manufacturing facilities in Bucharest, Prague, and Ankleshwar, Zentiva is rapidly expanding its reach in Europe and beyond.

Shares of Biocon Ltd. ended 2.11 percent down at Rs 274.25.

Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Tags

Previous Article

Adani open offer sees 28 lakh NDTV shares tendered by Day 3

Next Article

TVS Motor Company opens its first experience centre in Singapore 

Most Read

Market Movers

View All
Top GainersTop Losers
CurrencyCommodities
CompanyPriceChng%Chng